188889-04-5

Basic information

• Product Name: 1-Naphthalenol, 7-bromo-1,2,3,4-tetrahydro-4,4-dimethyl-1-(4-methylphenyl)-
• CAS NO: 188889-04-5
• Molecular Formula: C19H21BrO
• Molecular Weight: 345.279
• Mol File: 188889-04-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-Naphthalenol, 7-bromo-1,2,3,4-tetrahydro-4,4-dimethyl-1-(4-methylphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Naphthalenol, 7-bromo-1,2,3,4-tetrahydro-4,4-dimethyl-1-(4-methylphenyl)-(188889-04-5)
• EPA Substance Registry System: 1-Naphthalenol, 7-bromo-1,2,3,4-tetrahydro-4,4-dimethyl-1-(4-methylphenyl)-(188889-04-5)

Safety Data

• Hazardous Substances Data: 188889-04-5(Hazardous Substances Data)

Upstream product

• 106-38-7 para-bromotoluene 
• 166978-46-7 7-bromo-4,4-dimethyl-3,4-dihydro-2H-naphthalen-1-one 
• 4294-57-9 para-methylphenylmagnesium bromide 

Downstream Products

• 188889-06-7 6-bromo-1,1-dimethyl-4-(p-tolyl)-1,2-dihydronaphthalene 
• 204449-09-2 5,5-dimethyl-8-p-tolyl-5,6-dihydro-naphthalene-2-carbaldehyde 
• 204449-13-8 4-{1-[1-[5,5-Dimethyl-8-(5-methyl-thiophen-2-yl)-5,6-dihydro-naphthalen-2-yl]-meth-(E)-ylidene]-3,3-dimethoxy-propyl}-benzoic acid ethyl ester 
• 204449-10-5 4-{1-[1-(5,5-Dimethyl-8-p-tolyl-5,6-dihydro-naphthalen-2-yl)-meth-(E)-ylidene]-3,3-dimethoxy-propyl}-benzoic acid ethyl ester 
• 166978-45-6 5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenecarboxylic acid 
• 188888-33-7 ethyl 4-(5,5-dimethyl-8-(p-tolyl)-5,6-dihydronaphthalene-2-carboxamido)benzoate 
• 188888-45-1 ethyl 2-fluoro-4-[[(5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl)carbonyl]amino]-benzoate 
• 192762-68-8 ethyl 2,6-difluoro-4-({[5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]carbonyl}amino)benzoate 

Relevant articles and documents

Identification of highly potent retinoic acid receptor α-selective antagonists

The syntheses and full retinoid receptor characterization of a novel series of retinoic acid receptor α (RARα) antagonists, 1-5, are described. These compounds bind with high affinity to RARα but were completely inactive in gene transactivation. They were also potent and effective antagonists of retinoic acid (RA) induced gene transcription at RARα. Compounds 1-5 exhibited varying degrees of selectivity for RARα relative to RARβ/γ, with compound 5 being the most selective in both binding and functional antagonism assays. These compounds will be invaluable tools in delineating the physiological roles of RARα in development and in the adult animal and may themselves be useful therapeutic agents in human diseases associated with RARα.

Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities

Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

A new class of potent RAR antagonists: Dihydroanthracenyl, benzochromenyl and benzothiochromenyl retinoids

The synthesis and biological activity of a novel series of tricyclic retinoic acid receptor antagonists are described. These compounds bind with high affinity to the RARs and are potent antagonists of retinoid function in in vitro and in vivo systems.